Payment overview · 2025
General Payments
$134.91
7 reported records · 5 companies
Healthcare provider profile · identity verified
Ronald Polite, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1689775470
Verified facts
What the public records show
CMS Open Payments records show Ronald Polite, M.D. received $134.91 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.81 | 30.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.75 | 26.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.38 | 18.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.82 | 13.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.15 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $134.91 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 259 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
259 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 786 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 707 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 556 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 541 | 116 |
| Losartan Potassium | Losartan Potassium | 428 | 102 |
| Metformin Hcl | Metformin Hcl | 375 | 87 |
| Furosemide | Furosemide | 356 | 92 |
| Alprazolam | Alprazolam | 280 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 68 |
| Eliquis | Apixaban | 259 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 64 |
| Gabapentin | Gabapentin | 228 | 54 |
| Omeprazole | Omeprazole | 222 | 51 |
| Jardiance | Empagliflozin | 209 | 40 |
| Simvastatin | Simvastatin | 198 | 51 |
| Sertraline Hcl | Sertraline Hcl | 195 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 46 |
| Potassium Chloride | Potassium Chloride | 181 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 39 |
| Lisinopril | Lisinopril | 169 | 41 |
| Metformin Hcl Er | Metformin Hcl | 164 | 45 |
| Carvedilol | Carvedilol | 162 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 44 |
| Ozempic | Semaglutide | 158 | 31 |
| Trazodone Hcl | Trazodone Hcl | 158 | 41 |
| Allopurinol | Allopurinol | 152 | 38 |
| Prednisone | Prednisone | 140 | 103 |
| Tramadol Hcl | Tramadol Hcl | 139 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 29 |
| Meloxicam | Meloxicam | 130 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 34 |
| Mirtazapine | Mirtazapine | 122 | 23 |
| Atenolol | Atenolol | 118 | 25 |
| Divalproex Sodium | Divalproex Sodium | 112 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 23 |
| Ezetimibe | Ezetimibe | 95 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 37 |
| Famotidine | Famotidine | 91 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 34 |
| Lorazepam | Lorazepam | 90 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 23 |
| Pregabalin | Pregabalin | 80 | 18 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 19 |
| Alendronate Sodium | Alendronate Sodium | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 18 |
| Spironolactone | Spironolactone | 68 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 51 |
| Trulicity | Dulaglutide | 66 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 12 |
| Levetiracetam | Levetiracetam | 65 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 17 |
| Azithromycin | Azithromycin | 61 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Valsartan | Valsartan | 57 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 21 |
| Labetalol Hcl | Labetalol Hcl | 51 | suppressed |
| Ramipril | Ramipril | 50 | 13 |
| Benazepril Hcl | Benazepril Hcl | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | 15 |
| Methocarbamol | Methocarbamol | 46 | 17 |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 37 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 44 | 44 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Telmisartan | Telmisartan | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Finasteride | Finasteride | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ingrezza | Valbenazine Tosylate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134.91 · 7 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, EVENITY, INSPIRE, JARDIANCE, NURTEC ODT, PREVNAR 20, SHINGRIX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error